Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Gastrointestinal Stromal Tumor

Terminated

3

Start Date 05/20/2009

Age of Trial (yrs) 15.5

Stable Disease

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

EORTC 62063

EORTC AGITG FSG ISG SSG

Anne Kirkpatrick Project Manager - EORTC, Brussels, Belgium anne.kirkpatrick@eortc.be +32 2 7741691

Randomized

Oral

The contacts are either Anne Kirkpatrick at EORTC +32 2 7741691 or Allesandro Gronchi The Trial Coordinator at +39 02 23903234. Sites listed are not a complete list.

Participating Groups:
EORTC Soft Tissue and Bone Sarcoma Group(Coordinating Group)
Australasian Gastro-Intestinal Trials Group
French Sarcoma Group
Italian Sarcoma Group
Scandinavian Sarcoma Group

Alessandro Gronchi (Study Coordinator) - Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milano
Martine Van Glabbeke (Statistician) - EORTC, Brussels
Catherine Hermans (Data Manager) - EORTC, Brussels
Sandrine Marreaud (Coordinating Physician) - EORTC, Brussels